Tesamorelin (10mg vials)
Out of stock
Peptide Partners
Tesamorelin
Swipe right to view full table →
Save over 70%!
Product Format
10mg vials
Vial Size
10mg
Vial Capacity
3 mL
Box Combinations
20mg, 50mg, 100mg, 200mg
Cost per milligram
$4.49 – $6.10
Multi-vial Purity
99.81%
Endotoxin Screening
PASSED
Heavy Metals Screening
Purity Screening
Independently Tested
YES
Peptide Partners Manufacturer ID: WF03
Batch ID: TES202605
Research Studies
Study 1: Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4830873/
This study reports the development and validation of a qualitative method for the simultaneous detection of four GHRHs, including Tesamorelin, in human plasma. The method employs immunoaffinity purification using a polyclonal GHRH antibody followed by nano-ultrahigh performance liquid chromatography-high resolution/high accuracy tandem mass spectrometry (LC-HRMS/MS). The in vitro experiments demonstrated the metabolic stability of Tesamorelin. The method was validated for specificity, linearity, recovery, lower limit of detection, imprecision, and ion suppression/enhancement effects, proving its fitness for purpose in sports drug testing.
Researchers developed a highly sensitive method to detect Tesamorelin and other growth hormone-releasing hormones (GHRHs) in human plasma. This new test uses a combination of immunoaffinity purification and liquid chromatography-mass spectrometry to identify these substances with high accuracy. The study also investigated the stability of Tesamorelin in a laboratory setting and found it to be metabolically stable. This is significant for anti-doping applications as it provides a reliable method for detecting the use of these banned substances in athletes.
Study 2: Structural basis for activation of the growth hormone-releasing hormone receptor
Authors: Zhou F, Li JJ, Li XC, Jiang Y, Yang DH, Chen LN, Xu HE, Li MJ, Li XF.
Source: https://www.nature.com/articles/s41467-020-18945-0
This study elucidates the cryo-electron microscopy structure of the human growth hormone-releasing hormone receptor (GHRHR) in complex with its endogenous ligand GHRH and the stimulatory G protein (Gs). The structure reveals that GHRH binds to a novel site within the transmembrane domain of the receptor, which is distinct from the binding mode of other class B GPCRs. The study identifies key residues for GHRH binding and receptor activation, providing a structural basis for understanding the mechanism of action of GHRH and its analogues like Tesamorelin. This structural information is invaluable for the rational design of new therapeutic agents targeting the GHRHR.
Scientists have created a 3D map of the receptor in our bodies that Tesamorelin and other similar hormones bind to. This map, obtained using a technique called cryo-electron microscopy, shows exactly how the hormone ‘docks’ with the receptor to activate it. This is a crucial discovery because it helps us understand the fundamental mechanism of how Tesamorelin works at a molecular level. This knowledge can be used to design new and better drugs that target this receptor for various medical conditions.
Study 3: Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Authors: Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK.
Source: https://insight.jci.org/articles/view/140134
This study investigated the effects of Tesamorelin on hepatic transcriptomic and proteomic signatures in patients with HIV-associated non-alcoholic fatty liver disease (NAFLD). The researchers performed RNA sequencing on liver biopsies and proteomic analysis of plasma samples from patients treated with Tesamorelin or placebo. The results showed that Tesamorelin treatment was associated with downregulation of hepatic gene sets involved in inflammation, tissue repair, and cell division. Furthermore, a targeted proteomic analysis revealed that Tesamorelin modulated the levels of several plasma proteins that are linked to these pathways. These findings provide a molecular basis for the observed clinical benefits of Tesamorelin in reducing liver fat and fibrosis in this patient population.
In this study, researchers investigated how Tesamorelin affects the liver in people with HIV-associated fatty liver disease. They analyzed liver tissue and blood samples from patients treated with Tesamorelin and found that the drug changed the activity of genes involved in inflammation, tissue repair, and cell division. Specifically, Tesamorelin reduced the activity of genes that cause inflammation and scarring in the liver. This study provides important insights into the molecular mechanisms by which Tesamorelin improves liver health in this patient population.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
Kisspeptin-10
KSS2607
VI32
2026-07-02
99.71%
Kovera
View File
Reconstitution Solution
BAC202603
WF03
2026-07-13
99.9%
Retatrutide
RTT2613
99.77%
PT-141
PT202605
2026-06-25
99.74%
Tesamorelin
TES202607
2026-06-19
99.80%
TrustPointe
KPV
KV202606
2026-06-12
99.36%
Yes
BPC-157
BC202607
99.82%
Ipamorelin
IP202606
99.98%
Semaglutide
SM202607
99.96%
RTT202606
CJC-1295 ND
CJ202606
2026-06-10
99.88%
RT202607
2026-06-09
99.76%
Tirzepatide
TZ202605
99.55%
99.68%
99.70%
99.34%
99.65%
99.90%
NAD+
NDB202606
2026-05-28
GHK-Cu
CU202605
2026-05-13
99.67%
Epithalon
ET202604
99.86%
5-Amino-1MQ
AM202604
99.78%
2026-05-29
99.53%
Chromate
2026-06-11
99.22%
MOTS-c
MC202605
2026-06-08
99.94%
TB-500 (TB4)
TB202605
TES202605
RT202605
2026-05-27
99.75%
BAC202602
2026-05-14
CJC-1295 ND / Ipamorelin
CJIP202605
99.93%
Cagrilintide
CG202607
BPC-157/TB-500
BB202605
99.73%
CU202604
BC202604
99.72%
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin
CIT202604
2026-05-07
TES202604
2026-04-21
99.85%
DSIP
DS202605
KLOW Blend
KW202604
AOD-9604
AO202605
2026-04-20
CG202603
2026-04-14
MC202603
2026-04-04
RT202604
2026-04-16
99.54%
Sermorelin
SER202601
2026-04-01
Pinealon
PN202603
2026-04-03
SS-31
SS202601
Semax
SX202603
2026-03-31
99.91%
RT202603
2026-03-30
99.40%
GLOW Blend
GW202603
2026-03-25
TZ202603
2026-03-27
99.89%
BB202604
99.63%
TES202603
99.52%
2026-03-18
99.60%
Ipamorelin/CJC-1295 (No DAC)
CJIP202602
2026-02-27
99.92%
Thymosin Alpha-1
TA202602
2026-02-25
99.95%
KLOW
KW202602
2026-03-01
NDB202601
2026-02-07
SS202602
2026-02-08
MC202602
2026-02-09
99.41%
Selank
SEK202601
2026-01-29
Unbuffered NAD+
NDU202601
MZ21
2026-01-20
KV202601
IP202601
2026-01-14
TB500 (TB4)
TB202601
RT202602
2026-01-13
PT202512
2026-01-12
BioRegen
SM202601
2026-01-10
CAG202601
99.33%
TES202601
2025-12-29
BP202512
99.46%
BB202512
99.64%
GK202512
SH07
2025-12-19
99.79%
MC202512
2025-12-22
RP260130
SS202512
RP202601
DF05
CJIP202512
2025-12-09
RP202511
RP20251020
2025-11-10
RP20251001
2025-10-13
TZ20250915
2025-10-03
RP20250929
99.47%
Humanin
HP20250805
2025-09-19
YC20250807
99.87%
DS20250820
SY20250806
CJC/Ipamorelin
CI20250805
2025-09-11
99.84%
BP20250808
2025-09-05
99.99%
SM20250723
2025-08-27
TS20250722
2025-08-22
99.10%
CJ20250724
2025-08-20
99.43%
SM20250801
EJ12
IP20250721
2025-08-15
CU20250717
2025-08-09
TZ20250730
2025-08-08
ND20250503
2025-07-31
VIP
VP20250511
99.42%
CD20250708
2025-07-25
BPC/TB500
BB20250630
2025-07-17
TB20250614
Current Endotoxin Certifications
2026-06-30
Conforms
2026-06-22
2026-06-15
2026-05-18
2026-03-26
CJC-1295 ND/Ipamorelin
2026-03-17
TA202601
2026-01-28
TB500
2026-01-07
2026-01-06
2025-12-30
2025-12-08
2025-09-03
Bacteriostatic Water
BAC20250807
2025-08-11
2025-08-04
2025-07-29
2025-07-24
Current Heavy Metal Certifications
2026-07-01
2026-06-26
2026-06-13
2026-06-05
TB-500
2026-05-26
2026-05-24
2026-05-16
2026-04-26
2026-04-22
2026-05-05
2026-04-24
2026-04-02
2026-03-29
2026-01-26
2026-01-19
2026-01-08
2025-12-03
2025-11-24
2025-11-12
Current Sterility Certifications
Pass
2026-06-23
-
2026-04-12
BAC202601
2025-09-09
Meta-Z
MZR20250713
2025-08-26
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
USP <85> Bacterial Endotoxin Result: <x.xx EU/mLBecause it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge.
If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
CV stands for coefficient of variation, a measure of repeatability.
For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
This refers to the precision of the positive control (spiked sample).
Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
This tells us how much of the known endotoxin spike was recovered from your sample.
The acceptable range is 50–200% per USP <85>
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.